Ētahi atu korero ― Maori

Urticaria, te nuinga o te wā ka pā mai ki te tino weriweri kua piki ake. I ētahi wā ka haere tahi me te pupuhi o ngā kopa o raro. Ko te nuinga o te maimoatanga ko te karo i ngā kaipatu, mēnā ka mōhiotia. Kei roto i te rongoā tuatahi he antihistamines hou, ā, ka taea te whakatika ki ngā pōta teitei mēnā ka hiahiatia. Ko ētahi atu rongoā pērā i ngā antihistamines tawhito, te aukati H2, te kaitukino kaikawe leukotriene, te antihistamine kaha ake, me ngā akoranga poto o te corticosteroids ka taea te tāpiri hei tautoko. I roto i ngā kēhi, ka mau tonu te urticaria ahakoa ēnei mahi; ka tukuna pea ngā turoro ki ngā tohunga mō ētahi atu rongoā pērā i te omalizumab, cyclosporine rānei.
Urticaria commonly presents with intensely itchy raised welts. It is sometimes accompanied by swelling of the underlying tissues. Treatment primarily involves avoiding triggers, if known. First-line medication includes newer antihistamines, which can be adjusted to higher doses if needed. Other medications like older antihistamines, H2 blockers, leukotriene receptor antagonists, stronger antihistamines, and short courses of corticosteroids can be added as extra support. In cases where urticaria persists despite these measures, patients might be referred to specialists for additional therapies such as omalizumab or cyclosporine.

Ko tēnei arotake e whakaatu ana i ngā aratohu hou mō te rongoā i te urticaria me te tuku māramatanga hou mō ōna take.
This review outlines the latest guidelines for treating urticaria and offers new understandings of its causes.

Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), Omalizumab, Ciclosporin, and short courses only of systemic corticosteroids